Accessibility Menu
Bicycle Therapeutics Plc logo

Bicycle Therapeutics Plc(NASDAQ) BCYC

Market Cap$196.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-68%
5 Year-86%
1 Year-47%
1 Month-8%
$3.92
-1.51%
-0.06Today
After hours$3.90-$0.02 (-0.51%)
Bicycle Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 3.902026-08-14
Bicycle Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.47%USD 4.172026-08-07
1 month-7.58%USD 4.222026-07-15
3 month-12.36%USD 4.452026-05-15
Year to date-44.92%USD 7.082025-12-31
1 year-47.15%USD 7.382025-08-14
3 year-82.08%USD 21.762023-08-15
5 year-86.36%USD 28.592021-08-13
Since inception-67.5%USD 12.002019-05-23

Bicycle Therapeutics Plc Financials at a Glance

Market Cap

$196.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$61.21M

Net Income (TTM)

-$190.41M

EPS (TTM)

-$2.73

P/E Ratio

-1.43

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$3.92

Volume

468,117

Open

$3.95

Previous Close

$3.90

Daily Range

$3.87 - $3.97

52-Week Range

$3.75 - $9.16

Estimated Earnings Date

Oct 29, 2026

BCYC News

Foolcom-Featured.png

Bicycle (BCYC) Q2 Revenue Falls 69%

Motley Fool Markets TeamAug 8, 2025
research scientists drugs pharma biotech

Why Shares of Bicycle Therapeutics Were Rising on Monday

James HalleySep 11, 2023
Two people seated at a lab desk featuring a PC screen and microscope

Why Bicycle Therapeutics Stock Raced Ahead Today

Eric VolkmanJul 13, 2023
investor-shopping-for-dividend-stocks-getty

Here's Why Bicycle Therapeutics Stock Looks Ill Today

Cory RenauerApr 11, 2022
GettyImages-1149625161

Is Bicycle Therapeutics Stock a Buy?

Zhiyuan SunJun 13, 2020
pharma-manufacturing-clean-room-getty

3 Ultra-Risky Biotech Stocks That Could Make You Filthy Rich

Cory RenauerApr 21, 2020
biotech researcher

5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich

George Budwell, PhDMar 22, 2020
percent growth

2 High-Growth Stocks I’m Buying Right Now

George Budwell, PhDFeb 26, 2020

BCYC: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bicycle Therapeutics Plc

Bicycle develops new medicines for cancer and other serious diseases. Its main products help doctors target tumors more precisely. These treatments aim to improve options for patients with limited choices.

Products and Services

  • Bicycle Drug Conjugates: Synthetic molecules linked to toxins, designed to target cancer cells.
  • Bicycle Radioconjugates: Molecules attached to radioactive elements for cancer imaging and therapy.
  • Bicycle Imaging Agents: Used to help doctors see and select the right patients for treatment.
  • Bicycle Tumor-Targeted Immune Cell Agonists: Molecules that activate immune cells to attack tumors.
  • Collaborative Research Programs: Joint projects with pharmaceutical companies to develop new treatments in cancer, heart, and eye diseases.

Growth and Expansion

  • Formed major research collaborations with AstraZeneca, Sanofi, Genentech, Ionis, and Bayer since 2017.
  • Expanded product pipeline with new cancer drug candidates from 2020 to 2025.
  • Entered radiopharmaceutical supply agreements with Eckert & Ziegler and SpectronRx in 2025.
  • Reprioritized pipeline and reduced workforce by 30% in March 2026 to focus on next-generation therapies.
  • Discontinued some clinical trials in 2026 to concentrate resources on lead programs.

What Makes Bicycle Stand Out

Bicycle uses a unique technology to create small, synthetic molecules that can target disease sites with high precision. Its modular approach allows for rapid development of new treatments across different diseases. The company’s partnerships with global pharmaceutical firms support its research and expand its reach.

Five Things You Need to Know

  • Revenue was $48 million in Q4 2025, up 1193.3% from Q4 2024.
  • All revenue comes from research collaborations, not product sales.
  • Net loss was $25 million in Q4 2025, improved from $68 million in Q4 2024.
  • Cash and cash equivalents were $628.1 million as of December 31, 2025.
  • Operating expenses rose to $319.7 million in 2025, up 30.4% from 2024.

Bottom Line

Bicycle has evolved by focusing on targeted cancer therapies and strategic partnerships. Its adaptable technology and collaborations position it as a key player in innovative drug development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

288

CEO

Kevin Lee, PhD, MBA

Website

www.bicycletherapeutics.com

Headquarters

Cambridge, CAM CB22 3AT, GB

BCYC Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-343.69%

Net Income Margin

-311.11%

Return on Equity

-33.22%

Return on Capital

-39.48%

Return on Assets

-31.39%

Earnings Yield

-69.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$196.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.38M

Volume

468.12K

Avg. Volume

429.75K

Financials (TTM)

Gross Profit

$61.21M

Operating Income

-$210.36M

EBITDA

-$183.20M

Operating Cash Flow

-$205.72M

Capital Expenditure

$126.32K

Free Cash Flow

-$205.59M

Cash & ST Invst.

$510.05M

Total Debt

$13.68M

Bicycle Therapeutics Plc Performance Analysis

Bicycle Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,454,07423.6%
20232023-12-31USD 27,080,56187.4%
20242024-12-31USD 35,289,84330.3%
20252025-12-31USD 72,755,624106.2%
Bicycle Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30301.8%
Q42025-12-31308.7%
Q12026-03-31-98.2%
Q22026-06-30-29.1%
Bicycle Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.8042.5%
20232023-12-31USD -5.1034.2%
20242024-12-31USD -2.91-43.0%
20252025-12-31USD -3.179.0%
Bicycle Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3025.4%
Q42025-12-3165.9%
Q12026-03-31-200.0%
Q22026-06-3017.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$629.00K

-78.5%

Gross Profit

$629.00K

+100.9%

Gross Margin

100.00%

N/A

Market Cap

$196.47MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$682.18K

N/A

Employees

288

N/A

Net Income

-$50.33M

+36.2%

EBITDA

-$49.13M

+36.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$510.05M

-29.3%

Total Debt

$13.68M

+71.3%

Accounts Receivable

$47.42M

-21.9%

Inventory

$0.00

N/A

Long Term Debt

$13.68M

+435.6%

Short Term Debt

$0.00

-100.0%

Return on Assets

-31.39%

N/A

Return on Invested Capital

-37.63%

N/A

Free Cash Flow

-$49.87M

+31.9%

Operating Cash Flow

-$49.61M

+31.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADCTADC Therapeutics S.A.
$1.01-3.81%
FULCFulcrum Therapeutics, Inc.
$3.74+0.81%
NMRANeumora Therapeutics, Inc. Common Stock
$1.60-7.51%
CMPXCompass Therapeutics, Inc.
$2.25-0.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About BCYC

What is the current price of Bicycle Therapeutics Plc?

Bicycle Therapeutics Plc is trading at $3.90 per share.

What is the 52-week range for Bicycle Therapeutics Plc?

Over the past 52 weeks, Bicycle Therapeutics Plc has traded between $3.75 and $9.16.

How much debt does Bicycle Therapeutics Plc have?

As of the most recent reporting period, Bicycle Therapeutics Plc reported total debt of $15.21M.

How much cash does Bicycle Therapeutics Plc have on hand?

Bicycle Therapeutics Plc reported $510.05M in cash and cash equivalents in its most recent financial results.

What is Bicycle Therapeutics Plc’s dividend yield?

Bicycle Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services